Aligos Therapeutics, Inc. $ALGS Shares Acquired by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. raised its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 43.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 465,000 shares of the company's stock after buying an additional 140,000 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 7.61% of Aligos Therapeutics worth $3,836,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALGS. Heights Capital Management Inc. purchased a new position in Aligos Therapeutics in the 1st quarter valued at approximately $1,992,000. Readystate Asset Management LP purchased a new position in Aligos Therapeutics in the 1st quarter valued at approximately $375,000. AlphaQuest LLC purchased a new position in Aligos Therapeutics in the 1st quarter valued at approximately $130,000. Northern Trust Corp purchased a new position in Aligos Therapeutics in the 4th quarter valued at approximately $205,000. Finally, Golden State Wealth Management LLC boosted its position in Aligos Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 5,348 shares of the company's stock valued at $44,000 after buying an additional 2,674 shares during the period. Hedge funds and other institutional investors own 60.43% of the company's stock.

Aligos Therapeutics Price Performance

Shares of NASDAQ:ALGS traded down $0.16 on Thursday, reaching $10.56. The company's stock had a trading volume of 34,562 shares, compared to its average volume of 162,036. The stock's 50-day moving average is $9.03 and its two-hundred day moving average is $8.21. Aligos Therapeutics, Inc. has a 52-week low of $3.76 and a 52-week high of $46.80. The stock has a market capitalization of $64.91 million, a P/E ratio of -0.53 and a beta of 2.79.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($1.53) EPS for the quarter, beating analysts' consensus estimates of ($2.35) by $0.82. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%. The business had revenue of $0.97 million during the quarter, compared to analysts' expectations of $0.43 million. Equities analysts forecast that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright initiated coverage on shares of Aligos Therapeutics in a research report on Monday, August 18th. They set a "buy" rating and a $50.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $50.00.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).